
Bortiva 3.5mg Injection
Marketer
GLS Pharma Ltd.
Salt Composition
Bortezomib (3.5mg)
Overview Bortiva 3.5mg Injection
Carfilzomib 3.5mg Injection treats multiple myeloma and mantle cell lymphoma by inhibiting cancer cell proliferation. Administered intravenously by a healthcare professional, the dosage and frequency are determined by your physician based on your condition and may vary. Adhere strictly to your doctor's instructions; incorrect usage or overdose can lead to severe adverse effects. Therapeutic benefits may take weeks or months to manifest; discontinue only under medical supervision. Common side effects include fatigue, nausea, vomiting, and anorexia. Increased fluid intake is often recommended. Operating machinery or driving should be avoided due to potential drowsiness and dizziness. This medication can decrease blood cell counts (red and white blood cells), increasing infection risk. Regular blood tests monitoring blood cell levels, along with heart, liver, and uric acid levels, are essential. Prior to commencing Carfilzomib 3.5mg Injection, disclose any liver, kidney, heart conditions, or bleeding disorders to your physician. Report cognitive symptoms like memory impairment or difficulty concentrating immediately. Inform your healthcare provider of all other medications you are taking, as interactions may occur. This injection is contraindicated during pregnancy and breastfeeding; effective contraception is crucial for both partners during treatment.
Primary Ingredients of Bortiva 3.5mg Injection
No text provided. Please provide the text you wish to be rewritten.
Uses of Bortiva 3.5mg Injection
Myeloma and mantle cell lymphoma
Major Benefits of Bortiva 3.5mg Injection:
The medication will be administered by your physician or registered nurse; self-medication is strictly prohibited.
Common Side effects of Bortiva 3.5mg Injection:
- Low blood platelets
- Fatigue
- Peripheral neuropathy (tingling and numbness of feet and hand)
- Psychiatric disturbances
- Nausea
- Vomiting
- Loss of appetite
- Fever
- Anemia (low number of red blood cells)
- Diarrhea
- Decreased appetite
- Decreased white blood cell count (neutrophils)
- Constipation
How to use Bortiva 3.5mg Injection:
This medication will be administered by your healthcare provider. Self-medication is strictly prohibited.
How Bortiva 3.5mg Injection works:
The injectable drug Bortiva, at a 3.5mg dose, combats cancer by inhibiting the cellular breakdown of proteins. This protein accumulation within cancer cells ultimately triggers their demise.
SAFETY ADVICE
AlcoholUNSAFE
Concomitant use of Bortiva 3.5mg Injection and alcohol can lead to heightened somnolence.
PregnancyCONSULT YOUR DOCTOR
Using Bortiva 3.5mg Injection during pregnancy poses a confirmed risk to the fetus. Therefore, it's contraindicated. In exceptional, life-threatening circumstances, a physician might prescribe it if the potential benefits outweigh the known hazards. Always seek medical advice.
Breast feedingUNSAFE
Administration of Bortiva 3.5mg Injection is contraindicated while breastfeeding. Evidence indicates potential infant toxicity from this medication.
DrivingUNSAFE
Administering Bortiva 3.5mg Injection may induce adverse reactions potentially impairing driving capabilities. These reactions can include fatigue, vertigo, syncope, or visual disturbances, all of which might compromise safe driving.
KidneyCAUTION
Administering Bortiva 3.5mg Injection requires careful consideration in individuals with advanced kidney impairment. Dosage modification for Bortiva 3.5mg Injection might be necessary. Physician consultation is advised.
LiverCAUTION
Exercise caution when administering Bortiva 3.5mg Injection to individuals with hepatic impairment. Dosage modification of Bortiva 3.5mg Injection might be necessary. Physician consultation is advised.
What if you forget to take Bortiva 3.5mg Injection :
Omitting a scheduled dose of Bortiva 3.5mg Injection necessitates contacting your physician.
Facts to Know About Bortiva 3.5mg Injection
| Label | Value |
|---|---|
| Chemical Type | Phenylalanine-based Compounds |
| Developing Habits | No. |
| Treatment Category | Cancer Drugs |
